In addition, single cell studies of the tumor microenvironment should clarify whether STING signaling is heterogeneous and subject to evolution – previous work has shown that epigenetic silencing of STING can occur [29] and this could be a biomarker for tumors that would respond differentially to STING agonists. Here, STING1 is linked to neoplasm.